Biomarker Plasma Antineoplastic agents ACTH Immunohistochemistry Colon cancer Allelic imbalance BRAFV600E Radiotherapy Antibody-drug conjugate Adjuvant Locally advanced BRAF Safety Systemic therapy Androgen insensitivity Beta-catenin Colorectal carcinoma Colorectal cancer BRAF V600E Acute generalized exanthematous pustulosis Cancer Molecular targeted therapies Crizotinib Chemoresistance Dabrafenib ALK Adverse events Anti-PD-1 antibody Bisphosphonates Staging Langerhans cell histiocytosis Adjuvant FOLFOX Immune checkpoint inhibitor Prognostic Polyomavirus Nivolumab TNM classification Immunotherapy Adjuvant therapy Metastatic ALK rearrangement Lung adenocarcinoma Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy BRAFV600E mutation Cutaneous squamous cell carcinoma BRAFV600-mutant melanoma Surgical excision Merkel cell carcinoma Gastric bypass EGFR 2-chlorodeoxyadenosine Histiocytosis Non-small cell lung cancer Treatment Advanced melanoma Advanced Survival Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation Diagnosis Targeted therapy BRAF V600-mutation Children Biomarkers Metastatic cSCC Chemotherapy Sonic Hedgehog Cancer bronchique non à petites cellules Osimertinib Anti-PD-1 Invasive cutaneous squamous cell carcinoma Circulating tumor DNA Radiofrequency ablation Assisted reproductive techniques Prognosis Abdominal pain Cemiplimab Melanoma Anti-PD1 blockade AML Resistance Follow-up Mesenchymal stromal cells ADN tumoral circulant Body mass index Anti-Tumor pharmacology Immunomodulation Liver metastases Biliopancreatic diversion Anti-PD1 Bariatric surgery Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian Trametinib AZD9291 Oncology Anti-CTLA-4 Prevention Wnt Abscopal effect Circulating cell-free DNA